Lymphoma - small lymphocytic lymphoma

The PBS subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).

Treatment with idelalisib can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with SLL.

Patient eligibility

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing idelalisib.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised idelalisib for the treatment of SLL in writing and:

All applications must include a completed:

This authority application form can also be used for patients who received non-PBS subsidised idelalisib for the treatment of SLL before 1 September 2017.

Continuing treatment

To apply for continuing treatment contact the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 5 July 2018